Manager TitleAgeSince
Chief Executive Officer 53 2022-08-29
Director of Finance/CFO 55 2023-05-01
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 2015-08-31
Chairman 71 2021-04-14
Director/Board Member 59 2021-04-14
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +0.97%-0.20%+52.55%+125.61% 43.73B
Weighted average by Cap. +0.77%-0.50%+56.58%+134.21%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock